Nuwellis, Inc. (NUWE)

Nuwellis' stock price has significantly declined over the past year. Recent events include the completion of the acquisition of Rendiatech Ltd, the announcement that the pediatric category achieved approximately 50% of total U.S. revenue in 2025, the announcement of a software update to its Aquadex SmartFlow ultrafiltration platform, and the receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for innovative dual lumen midline catheter technology. Nuwellis, Inc. is expected to release its Q1 2026 earnings on May 12, 2026, before market open.

Based on historical stock price data, May has a low probability of positive returns, while June has the highest probability of positive returns. This seasonality analysis is based on stock performance rather than direct product demand, but it can reflect investor sentiment and activity around certain periods.

Nuwellis, Inc. is a medical device company focused on developing and commercializing solutions for fluid overload, particularly in patients with cardiorenal conditions. Their primary product is the Aquadex FlexFlow System, an ultrafiltration system designed to remove excess salt and water from patients with hypervolemia who have not responded to traditional treatments. The Aquadex system is FDA-cleared for use in both adult and pediatric patients weighing 20 kg or more.

Nuwellis, Inc. is headquartered in Eden Prairie, Minnesota, USA, and sells its products to hospitals and clinics through a direct salesforce in the United States. Internationally, Nuwellis distributes its products through independent specialty distributors primarily in countries such as Austria, Brazil, and the Czech Republic. The company also has a wholly-owned subsidiary in Ireland. In 2025, Nuwellis' pediatric footprint expanded to 47 centers nationwide in the U.S., including six of the top 10 children's hospitals.

Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies. The company's Aquadex therapy platform is clinically proven and designed to provide precise ultrafiltration. Positive events include continued momentum in its pediatric category, receipt of a Notice of Allowance for innovative dual lumen midline catheter technology, an Aquadex software update, and the acquisition of Rendiatech Ltd. However, the significant decline in stock price and negative profit margins indicate ongoing financial challenges.

Nuwellis, Inc. has 13 institutional owners and shareholders who have filed 13D/G or 13F forms with the SEC, holding a total of 130,548 shares. Major institutional owners include Sabby Management, LLC, DRW Securities, LLC, and Geode Capital Management, LLC. Individual insiders own approximately 1.01% of the company, and the general public holds the largest portion, at 94% of shares. Shareholders have experienced substantial dilution in the past year.